The partnership combines Sciwind’s disease biology expertise and clinical development capabilities with SynerK’s proprietary conjugate-based siRNA delivery technology and expertise in RNAi therapeutics development

SAN FRANCISCO, California. and HANGZHOU, China, September 26, 2022 /PRNewswire/ — Sciwind Biosciences, a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies to treat metabolic diseases, and SynerK, a leader in the discovery and development of RNAi therapeutics, announced today that that they have entered into a joint research partnership to discover and develop new therapeutics based on small interfering RNA (siRNA) technology for the treatment of hepatic and metabolic diseases characterized by an unmet medical need.

This partnership will combine the two companies’ expertise in discovering and developing innovative therapies for major human diseases. Through this collaboration, the two companies will work together to identify novel therapeutic targets that play critical roles in disease biology across a broad spectrum of hepatic and metabolic diseases and to discover and develop novel siRNA therapeutics against these targets.

“We are very excited to have the opportunity to work with the SynerK team and leverage SynerK’s proprietary siRNA technology platform to discover new therapies to treat chronic diseases for which effective treatments are still badly needed,” said Dr. Weidong Zhong, President of Sciwind Biosciences. “This research partnership will provide both companies with exciting opportunities to explore new disease targets or targets that have not been successfully modulated by traditional therapeutic modalities such as proteins or small molecule drugs.”

“We are pleased to have entered into this research collaboration with Sciwind, an industry leader in the discovery and development of innovative therapies for metabolic diseases. Sciwind’s deep insight and knowledge of disease biology is invaluable to…